Últimas noticias sobre RAPT Therapeutics (NASDAQ:RAPT) Bolsa

RAPT Therapeutics

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

RAPT Therapeutics Inc

Wolfe downgrades RAPT, but still sees "immense" upside potential

RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity

TimesSquare Capital U.S. Small/Mid Cap Growth Q1 2024 Commentary

RAPT Therapeutics to cut 40% of workforce to save cash

H.C. Wainwright analyst Ram Selvaraju reiterated a Hold rating on RAPT Therapeutics (RAPT – Research Report) today. The company's shares closed yes...

RAPT Therapeutics (RAPT) Gets a Hold from H.C. Wainwright

RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus

RAPT Therapeutics GAAP EPS of -$0.71 beats by $0.05

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>RAPT Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/rapt-stock-quote/"><strong>RAPT</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>RAPT Therapeutics reported earnings per share of -71 cents. This was above the analyst estimate for EPS of -72 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/rapt-stock-earnings-rapt-therapeutics-for-q2-of-2024/">RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q2 2024

In a report released today, Leon Wang from Barclays maintained a Hold rating on RAPT Therapeutics (RAPT – Research Report), with a price target of ...

Barclays Remains a Hold on RAPT Therapeutics (RAPT)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alnylam Pharma (ALNY – Research Report), RAPT Ther...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY), RAPT Therapeutics (RAPT) and Liquidia Technologies (LQDA)

ALNY

ASND

ATRC

BMBL

CYBR

ESAB

EXPO

FIVE

FROG

FRPT

GLBE

KRYS

LQDA

MSTR

MTDR

NICE

ONTO

RAPT

SMAR

SMCI

SYNA

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT

Press Releases

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

Earnings

RAPT Therapeutics Reports First Quarter 2024 Financial Results

News

Legal

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against RAPT Therapeutics, Inc. and Encourages Investors to Contact the Firm

RAPT Therapeutics Reports Second Quarter 2024 Financial Results

Allakos

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

Aerovate Therapeutics, Inc. - Common Stock

Aerovate Therapeutics

Celularity

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

CEL-SCI

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Elicio Therapeutics

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

Immuneering Corporation - Class A Common Stock

Immuneering

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

IO Biotech

Kronos Bio

Kezar Life Sciences

MAIA Biotechnology

Mural Oncology

Omega Therapeutics

OS Therapies

Renovaro

Reneo Pharmaceuticals, Inc. - Common Stock

Reneo Pharmaceuticals

Serina Therapeutics

Spero Therapeutics

Barclays

JP Morgan

Leerink Partners

Berenberg

Comments

RAPT Therapeutics

Noticias

Últimas noticias sobre RAPT Therapeutics (NASDAQ:RAPT) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL